---
title: "Darzalex (daratumumab) in multiple myeloma: Storage and supply questions"
description: "Storage and supply questions on Darzalex (daratumumab) in multiple myeloma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: How supplied. Questions: What are the NDC numbers for Darzalex and Darzalex Faspro? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/storage-and-supply"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Darzalex (daratumumab) in multiple myeloma: Storage and supply questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Darzalex](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf), [Darzalex Faspro](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf)

Questions that apply to every indication of Darzalex are on [Darzalex (daratumumab), all indications](https://www.evicenter.com/medical-information/darzalex).

## How supplied

<a id="darzalex-ndc"></a>

### What are the NDC numbers for Darzalex and Darzalex Faspro?

> “How Supplied
> DARZALEX<sup>®</sup> (daratumumab) injection is a colorless to pale yellow, 
> preservative-free solution for intravenous infusion.
> NDC 57894-502-05 and NDC 57894-505-05 each contain one 100 mg/5 mL 
> (20 mg/mL) single-dose vial
> NDC 57894-502-20 and NDC 57894-505-20 each contain one 400 mg/20 mL 
> (20 mg/mL) single-dose vial”

Source: [DARZALEX: DARZALEX®, page 16, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=16)

> “DARZALEX FASPRO<sup>®</sup> (daratumumab and hyaluronidase-fihj) injection is a 
> sterile, preservative-free, colorless to yellow, and clear to opalescent solution 
> for subcutaneous use supplied as individually packaged single-dose vials 
> providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 
> 15 mL (NDC 57894-503-01).”

Source: [DARZALEX: DARZALEX FASPRO®, page 19, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=19)

Note: Both passages are from the How Supplied section of the Prescribing Information: the first for DARZALEX (intravenous), the second for DARZALEX FASPRO.

## Related pages
- [Medical information: Darzalex (daratumumab): Multiple myeloma](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma)
- [Indication](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/guidelines)
